FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 29, 2016--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that, effective
March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume
the role of Executive Chairman of the company. John F. Milligan, PhD,
currently President and Chief Operating Officer, will be promoted to CEO
and appointed to the company’s Board of Directors.
John Martin joined Gilead in 1990 and was appointed Chief Executive
Officer in 1996 and Chairman of the Board in 2008. John Milligan also
joined Gilead in 1990 and was appointed Chief Operating Officer in 2007
and President in 2008.
“John Martin has led Gilead as CEO for the past 20 years, and under his
stewardship, the company has developed and delivered therapeutic
advancements to millions of people around the world. His legacy is clear
– and the vision he has set will continue with his contributions as
Executive Chairman,” said John Cogan, PhD, Gilead’s Lead Independent
Director.
“Over the past 25 years, John Milligan has distinguished himself as an
exceptional leader, serving in diverse management roles and overseeing
multiple phases of growth and expansion into new therapeutic areas and
geographies. The Board of Directors and I are confident in his ability
to lead Gilead into the future,” commented John Martin.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Gilead has operations in more
than 30 countries worldwide, with headquarters in Foster City,
California.
Forward-Looking Statement
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2015, as filed
with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
statement.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005255/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.InvestorsPatrick O’Brien, 650-522-1936orMediaAmy
Flood, 650-522-5643
